Skip to main content

Table 2 Subjects' echocardiography data at baseline and after 26 weeks of treatment.

From: Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

Value Pioglitazone group
(n = 15)
Insulin glargine group
(n = 15)
P-value
LVDD (mm) 47.6 ± 4.0 48.7 ± 4.5 0.37
IVS (mm) 10.2 ± 0.9 10.4 ± 1.6 0.85
POST (mm) 9.0 ± 1.0 9.1 ± 1.4 0.95
LVM (g) 160 ± 33 173 ± 56 0.55
LVD vol (ml) 104 ± 23 101 ± 21 0.88
LVS vol (ml) 39 ± 11 36 ± 11 0.34
EF (%) 62 ± 5 65 ± 5 0.21
LA vol (ml) 55 ± 14 58 ± 19 0.56
Change LVM (%) 7 ± 14 1 ± 11 0.25
Change LVD vol (%) 11 ± 19 1 ± 5 0.02
Change LVS vol (%) 2 ± 15 2 ± 13 0.74
Change EF (%) 6 ± 10 0 ± 6 0.09
Change LA vol (%) 17 ± 17 2 ± 6 <0.01